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Abstract
Background: Chronic brain pathology and pre-stroke cognitive impairment (PCI) is predictive of post-stroke
dementia. The aim of the current study was to measure pre-stroke neurodegenerative and vascular disease burden
found on brain MRI and to assess the association between pre-stroke imaging pathology and PCI, whilst also
looking for potential sex differences.
Methods: This prospective brain MRI cohort is part of the multicentre Norwegian cognitive impairment after stroke
(Nor-COAST) study. Patients hospitalized with acute ischemic or hemorrhagic stroke were included from five
participating stroke units. Visual rating scales were used to categorize baseline MRIs (N = 410) as vascular,
neurodegenerative, mixed, or normal, based on the presence of pathological imaging findings. Pre-stroke cognition
was assessed by interviews of patients or caregivers using the Global Deterioration Scale (GDS). Stroke severity was
assessed with the National Institute of Health Stroke Scale (NIHSS). Univariate and multiple logistic regression
analyses were performed to investigate the association between imaging markers, PCI, and sex.
Results: Patients’ (N = 410) mean (SD) age was 73.6 (±11) years; 182 (44%) participants were female, the mean (SD)
NIHSS at admittance was 4.1 (±5). In 68% of the participants, at least one pathological imaging marker was found.
Medial temporal lobe atrophy (MTA) was present in 30% of patients, white matter hyperintensities (WMH) in 38% of
patients and lacunes in 35% of patients. PCI was found in 30% of the patients. PCI was associated with
cerebrovascular pathology (OR 2.5; CI = 1.4 to 4.5, p = 0.001) and mixed pathology (OR 3.4; CI = 1.9 to 6.1, p = 0.001)
but was not associated with neurodegeneration (OR 1.0; CI = 0.5 to 2.2; p = 0.973). Pathological MRI markers,
including MTA and lacunes, were more prevalent among men, as was a history of clinical stroke prior to the index
stroke. The OR of PCI for women was not significantly increased (OR 1.2; CI = 0.8 to 1.9; p = 0.3).
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Conclusions: Pre-stroke chronic brain pathology is common in stroke patients, with a higher prevalence in men. Vascular
pathology and mixed pathology are associated with PCI. There were no significant sex differences for the risk of PCI.
Trial registration: NCT02650531, date of registration: 08.01.2016.
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Background
Stroke is a leading cause of death with high morbidity
rates seen worldwide. Up to 50% of stroke survivors are
left chronically disabled [1], thus posing a great burden
on public health. Around 20% of stroke survivors are at
risk of developing post-stroke dementia [2, 3]. To under-
stand the impact of stroke on the risk of post-stroke de-
mentia, pre-stroke cognitive status, including pre-stroke
dementia and pre-stroke cognitive impairment (PCI),
must be taken into account [4, 5]. Few studies have
looked at risk factors for PCI [6]. Pre-stroke dementia is
more widely studied than pre-stroke cognitive impair-
ment and is found in around 9–14% of stroke patients
[7]. Pre-stroke dementia is associated with older age at
onset, greater prevalence of atrial fibrillation, a history of
stroke, heart failure and premorbid use of anticoagulants
and anti-hypertensive medication [8]. Additionally,
female stroke survivors are more likely to suffer from
pre-stroke dementia [3], which has been attributed to
the fact that women generally are older than men at the
time of their first stroke [9]. Pre-stroke chronic brain
changes have been shown to reduce the threshold for
developing post-stroke dementia [7]; moreover, changes
such as cerebral atrophy [4] medial temporal lobe atro-
phy [9] and the number of old infarcts on CT scans [10]
have been shown to be associated with PCI. In a review,
Mok et al. concluded that pre-stroke Alzheimer’s disease
pathology and sporadic small vessel disease are the
most important pathologies associated with pre-stroke
dementia [11].
Both population based studies and studies of stroke
patients have measured PCI, many of them focusing on
pre-stroke dementia [5, 12]. However, little is known
about which neuroimaging biomarkers have the stron-
gest association with PCI. Neurodegeneration in the
form of medial temporal lobe atrophy (MTA) might
occur in normal aging or as part of neurodegenerative
diseases [13]. Further, neurodegeneration often coexists
with cerebrovascular disease [14], but knowledge on the
combined role of small vessel disease and neurodegener-
ation in the pathogenesis of PCI is limited.
While there is increasing interest in sex differences in
ischemic and hemorrhagic stroke, it focuses mainly on
epidemiology, risk factors, prevention and treatment
recovery. Stroke incidence is higher in men, but more
women are affected because of their longevity [15, 16].
Research on sex differences in neuroimaging markers
predominantly addresses the two main imaging markers
of cerebrovascular disease and neurodegeneration: white
matter hyperintensities (WMH) and medial temporal
lobe atrophy (MTA). WMH in particular is more severe
in women [17, 18].
There is increasing evidence that female sex is a
significant predictor of pre-stroke disability [19, 20],
and that pre-stroke cognitive impairment leads to
worse stroke outcome [21]. However, the association
of neuroimaging pathology, female sex and PCI is
understudied [22].
More knowledge on the extent of pre-stroke chronic
pathology and its impact on PCI will help increase the
understanding of the pathogenesis of post-stroke cogni-
tive impairment. The use of readily available visual scales
to evaluate the burden of both neurodegenerative and
vascular brain changes gives clinicians access to import-
ant bedside information. The assessment of pre-stroke
imaging pathology might help to predict the develop-
ment of cognitive decline after an acute stroke.
The objectives of the current study were to 1) measure
pre-stroke neurodegenerative and vascular disease path-
ology found on brain MRI, 2) describe the association
between pre-stroke neuroimaging features and PCI, and
3) investigate possible sex differences in the risk of PCI.
We hypothesized that pathological changes associated
with both small vessel disease and neurodegeneration
are associated with PCI and that there is a higher burden
of brain changes in women.
Materials and methods
The Norwegian cognitive impairment after stroke (Nor-
COAST) study is a prospective longitudinal multi-centre
cohort study [14]. Patients admitted to the stroke units
at five Norwegian hospitals were recruited starting in
May 2015 and ending in March 2017. Patients eligible
for participation in Nor-COAST were included accord-
ing to the following criteria: 1) hospitalized with acute
ischemic or hemorrhagic stroke, 2) within 1 week after
symptom onset, 3) age over 18 years, and 4) fluent in a
Scandinavian language. Exclusion criteria were 1) symp-
toms explained by other disorders than ischemic brain
infarct or intracerebral hemorrhages and 2) expected
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survival of less than 3 months after stroke based on a
clinical assessment by experienced stroke physicians
[14]. Inclusion criteria for MRI were 1) inclusion in Nor-
COAST and 2) ability to cooperate during MRI. Exclusion
criteria for MRI were 1) severe functional impairment
making MRI impossible to perform; 2) medical contra-
indications for MRI, such as claustrophobia or pacemaker;
and 3) refusal of patient to participate in MRI.
Patients were asked to participate in the MR part of
the study after they were included in the Nor-COAST
study. The participation in this imaging sub-study of
Nor-COAST was voluntary. As length of stay is often
very short, some patients were discharged before they
were asked, others lived too far from the hospital to
come back after discharge. The specific reasons for the
individual patient withdrawal/non-inclusion were unfor-
tunately not recorded.
To evaluate whether the included patients are repre-
sentative of the whole Nor-COAST study population, we
compared the clinical characteristics and risk factors of
patients with and without MRI.
MRI acquisition
A study-specific brain MRI was acquired at one of five
different sites in the acute/subacute phase of the stroke
(i.e. 2–7 days after symptom onset). The study protocol
consisted of a 3D T1-weighted sequence, axial T2, 3D
Fluid attenuated inversion recovery (FLAIR), diffusion
weighted imaging (DWI), and susceptibility weighted
imaging (SWI). Details about the MRI protocol can be
found in Supplementary Table 1. For a number of pa-
tients without a study-specific brain MRI, a clinical MRI
scan was available for visual analysis. The clinical MRI
sequences were acquired with different sequence param-
eters than the study-specific MRIs but were suitable for
visual rating (Fig. 1).
Image analysis
Only brain changes unrelated to acute stroke were ana-
lyzed using validated visual rating scales for markers of
neurodegenerative disease [23]. Small vessel disease fea-
tures were rated according to the Standards for Report-
ing Vascular Changes on Neuroimaging (STRIVE)
recommendations [14]. The extent of white matter
hyperintensities (WMH) of presumed vascular origin
was classified according to the widely used Fazekas scale
[24] using the 3D FLAIR sequence and categorized as
normal or pathological based on the score and age [25].
Edema associated with the acute stroke lesion was not
scored as WMH. Lacunes of presumed vascular origin
Fig. 1 Flowchart of patient inclusion to this study
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were assessed on the 3D FLAIR sequence and catego-
rized as present/not present; they were always regarded
as pathological [26]. Parenchymal defects with significant
loss of volume without corresponding diffusion restric-
tion were considered old infarcts. Silent infarct was
defined in patients with visible MRI changes in either
lacunes or cortical/subcortical infarct but no record of
previous clinical infarct. Microbleeds, i.e. the existence
of more than or equal to two (≥ 2) hypointense lesions
on SWI [27], were registered as present/not present [28].
Since microbleeds and lacunes were always regarded as
pathological, their occurrence was not further evaluated.
Medial temporal lobe atrophy (MTA) was assessed
according to the established MTA scale [29]. MTA was
categorized as normal or pathological depending on
score and age [23]. Posterior atrophy was assessed ac-
cording to the posterior atrophy (PA) scale [30]. A value
of ≥2 was considered pathological in patients below 95
years of age [23]. Ventricular enlargement, which is an
indirect measure of global cerebral atrophy, was mea-
sured using the Evans index (EI) [31] and categorized as
normal or pathological using sex- and age-dependent
reference values [32].
Patients were clustered into 1) a neurodegeneration
group, with pathological scores for MTA, PA or EI and
no pathological imaging markers of cerebrovascular
disease; 2) a cerebrovascular group, with pathological
scores for WMH, lacunes or microbleeds, and no patho-
logical imaging markers of neurodegeneration; 3) a
mixed group, with patients with pathological scores for
imaging markers from both categories 1 and 2; and 4)
a normal group, with no pathological score on visual
rating of brain MRI.
Reliability
To facilitate rating consistency between the two partici-
pating neuroradiologists (TS, MKB), a pilot dataset of 20
MRI scans was randomly selected and all relevant scales
(MTA, Fazekas, PA, EI, microbleeds) were scored. The
possible causes of differing results were then evaluated
and discrepencies were resolved in a consensus meeting.
Subsequently, 30 new randomly selected scans were
scored to evaluate the inter-rater variability. The same
dataset was scored again by one neuroradiologist (TS) to
evaluate the intra-rater reliability (please see Supplemen-
tary figure 1 for an overview of the process). The final
visual assessment of the total 410 patients included in
this study was done by one neuroradiologist (TS). No
cognitive assessment results were accessible by the neu-
roradiologists before completion of the visual ratings.
The inter-rater and intra-rater agreement measured in per-
cent was excellent for WMH, MTA, PA, and microbleeds,
and good for lacunes. The detailed results of reliability testing
of visual ratings are presented in Supplementary Table 3.
Cognitive assessment and cerebrovascular risk factors
The Global Deterioration Scale (GDS) was used for the
evaluation of PCI. The GDS is a global measure of cog-
nitive function originally designed for the evaluation of
AD, but it has also been shown to be valid for measuring
vascular dementia [33–36]. The assessment was per-
formed at baseline by experienced research nurses who
interviewed caregivers about the patients’ cognition the
last weeks before suffering an acute stroke. The GDS is
a 7-point scale with higher scores indicating more im-
paired cognition [36]. .Patients with a GDS score of 2
were categorized as having very mild cognitive/subjective
cognitive impairment [36]. GDS of 2 or higher is the first
stage on the scale that represents cognitive symptoms,
and it was rated as pathological [37].
The pre-stroke modified Rankin Scale (mRS) was used
to measure general functioning and the degree of dis-
ability in daily activities [38]. Criteria used in defining
clinical diagnoses and risk factors in the Nor-COAST
study were atrial fibrillation (AF), defined as presence of
atrial fibrillation on ECG in the past or during the
present hospital stay; hypertension (HT), defined by use
of anti-hypertensive drugs or lifestyle modification treat-
ment (including physical activity, weight control, heart
healthy diet, and smoking cessation) at the time of the
index stroke; hypercholesterolemia, defined as total chol-
esterol ≥6.2 mmol/L or LDL ≥ 4.1 mmol/L or using
cholesterol-lowering medication; diabetes mellitus (DM),
defined by presence in medical records or use of antidia-
betic medication, or as HbA1c ≥ 6.5%; previous stroke,
defined by a history of stroke in medical records; and
stroke severity, assessed by the National Institute of
Health Stroke Scale (NIHSS) [39] at admittance. The
ischemic stroke subtype was defined according to the
Trial of ORG 10172 in Acute Stroke Treatment
(TOAST) classification [40].
Statistical analysis
For group comparisons, the Mann-Whitney U test was
used for the continuous variables, and the chi-square
test was used for the binary variables. The odds ratio
(OR) of having PCI was calculated through a univariate
logistic regression analysis including sex, pathological
imaging group, silent infarcts, hypertension, atrial fibril-
lation, and clinically acknowledged previous stroke. The
relationship between sex and pathological imaging find-
ings was modelled using logistic regression, with male
sex as the reference group. Since age represents an im-
portant potential confounding variable, it was adjusted
for in the logistic regression models. This is also true for
models where brain imaging markers, which were
already age-adjusted, were used as explanatory variables.
The relationship between the imaging groups and the
existence of PCI was modelled using a multiple logistic
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regression analysis with the normal group as the
reference group. We additionally evaluated the effects of
imaging group, age, and education as confounding vari-
ables, as these values were significantly different between
men and women. We evaluated the effect of the inter-
action between sex and imaging group, by adding it to
the logistic regression model. Whenever sex was in-
cluded in a logistic regression analyses as an explanatory
variable, male sex was defined as reference.
All effect sizes are represented by ORs with 95% confi-
dence intervals (CI). The logistic regressions were done
with the help of the statsmodels package version 0.10.1
for Python version 3.6.7. Two-sided p-values below 0.05
were considered to indicate statistical significance. Re-
producibility of ratings was evaluated with percentage of
agreement and weighted Cohen’s kappa [41] with help
of Stata statistical software [42].
Results
Study population
A total of 410 patients were included in the study (Fig. 1).
The mean (SD) age was 73.6 (±11) years, 182 (44%) were
female, the mean (SD) NIHSS at admission was 4.1 (±5).
The population characteristics and cerebrovascular risk
factors are summarized in Table 1.
Comparison of included and excluded patients showed
that those included were significantly more likely to have
hypercholesterolemia and less likely to have suffered a
hemorrhagic stroke (see Supplementary Table 2). Apart
from that, the included patients were overall representa-
tive for the rest of the Nor-COAST population, and
there was no difference in pre-stroke GDS. More details
can be found in Supplementary Table 2.
Imaging findings
Out of all participants, 68% had at least one pathological
imaging marker. MTA was present in 30%, WMH in
38%, and lacunes in 35%. The mean age (SD) of the pa-
tients with a normal brain was 70 (± 12.9) years com-
pared to 75 (± 10.2) years for those with pathological
findings (p < 0.001). Table 2 summarizes the imaging
findings for the population overall and grouped by sex.
Cognitive assessment
We found that 100 of the 276 patients (36%) with base-
line pathological findings also had PCI, whereas 25 of
the 143 patients (18.9%) with normal MRI had PCI. The
highest percentages of patients with PCI were found in
the cerebrovascular group (37.5%) and in the mixed








Age at stroke, years (mean (±SD)) 410 73.6 (±11) 75.0 (±12) 72.5 (±11) 0.003
Living alone (N(%)) 410 152 (37.0) 88 (48.0) 64 (28.0) 0.05
Education (mean years(±SD)) 410 12.1 (±4) 11.4 (±3) 12.7 (±4) 0.0001
NIHSS at admission (0-42) (mean (±SD)) 405 4.1 (±5)a 4.3 (±5) 3.9 (±5) 0.34
Hemorrhagic stroke (N(%)) 395 27 (7.0) 12 (7.0) 15 (7.0) 0.56
Pre-stroke GDS (1-7) (mean (±SD)) 407 1.5 (±1) 1.6 (±1) 1.5 (±1) 0.11
Pre-stroke mRS (0-6) (mean (±SD)) 408 2.2 (±1) 2.4 (±1) 2.1 (±1) 0.005
TOAST classification (N) 368 368 166 202 0.282*
Large vessel disease 39 (10.6) 14 (8.3) 25 (12.4)
Cardioembolic disease 84 (22.8) 33 (19.9) 51 (25.3)
Small vessel disease 89 (24.2) 39 (23.5) 50 (24.8)
Other etiology 7 (1.9) 4 (2.4) 3 (1.5)
Undetermined etiology 149 (40.5) 76 (45.8) 73 (36.1)
History of:
Atrial fibrillation (N(%)) 407 65 (16.0) 25 (14.0) 40 (18.0) 0.06
Diabetes (N(%)) 407 77 (19.0) 34 (19.0) 43 (19.0) 0.31
Hypertension (N(%)) 410 196 (48.0) 82 (45.0) 114 (50.0) 0.02
Hypercholesterolemia (N(%)) 407 155 (38.1) 61 (33.7) 94 (41.6) 0.103
Previous stroke (N(%)) 410 66 (16.0) 22 (12.0) 44 (19.0) 0.01
Values are displayed as means (SD) and frequencies (%) for all patients and grouped by sex. Values are mean (±SD) for continuous variables and N (%) for binary
variables. For group comparisons we used we used Mann-Whitney U test for continuous variables and chi-square test for binary variables. NIHSS National
Institutes of Health stroke scale, mRS modified Rankin Scale, GDS Global Deterioration Scale, SD standard deviation. Previous stroke is clinically acknowledged
stroke. aThe median (IQR) of the NIHSS was 3 (0 to 24). *p-value of chi-squared test of TOAST classification contingency table
Schellhorn et al. BMC Geriatrics          (2021) 21:362 Page 5 of 10
group (44%) while the lowest prevalence of PCI was
found in the neurodegeneration group (19%).
The odds ratio (OR) of having PCI for patients with
clinically acknowledged previous infarct was 2.9 (95% CI
1.7–5.0, p < 0.001), atrial fibrillation was 1.1 (0.6–1.9,
p = 0.8), silent infarcts was 0.9 (0.5 to 1.8, p = 0.8), and
hypertension was 1.3 (0.87–2.0, p = 0.2).
The OR (95% CI) of PCI for the cerebrovascular
groups was 2.5 (1.4–4.5, p = 0.001) compared to the nor-
mal group. The OR (95%) of PCI was 3.4 (1.9–6.1, p =
0.001) for the mixed pathology group and 1.01 (0.5–2.2,
p = 0.973) for the neurodegeneration group (Table 3).
Sex differences
Female patients were older (by 2.5 years on average)
than men, had less education, and had a higher pre-
stroke modified Rankin Scale (mRS) score than men.
Women were less likely to suffer from hypertension and
had fewer previous clinical strokes (Table 1).
Female patients were less likely to show more than
one pathological imaging finding and had fewer lacunes
and less pathological MTA (Table 2).
The OR (95% CI) of PCI for women compared to men
was 1.2 (0.8 to 1.9, p = 0.3), which showed that female
sex was not significantly associated with PCI. There was
no significant interaction of sex and pathological im-
aging group. The OR (95% CI) for the interaction of sex
and cerebrovascular group was 2.1 (0.65 to 6.5, p =
0.217), the OR (95% CI) for the interaction of sex and
mixed group was 2.0 (0.59 to 6.8, p = 0.257), and the
interaction of sex and neurodegenerative group was 1.4
(0.3 to 8.1, p = 0.681).
Discussion
The first aim of this study was to measure pre-stroke
neurodegenerative and vascular disease pathology found
on brain MRI. Pre-stroke pathology was present in the
brain MRIs of more than two thirds of all of the patients
in the current study. More than half of all of the patients
had markers of small vessel disease exceeding what is
normal for their age according to published pathological
cut-offs. One in three had pathological neurodegenera-
tive changes. WMH was the most prevalent imaging
marker of small vessel disease, and MTA was the most
prevalent imaging marker of neurodegeneration. Our re-
sults are consistent with previous studies using visual
evaluation of similar populations. Imaging markers of
both small vessel disease and neurodegeneration are fre-
quently present in patients with stroke [43–45]. Differ-
ent studies have found MTA in the range of 10–75% of
Table 2 Pathological MRI findings
Total n/N (%) Female n/N (%) Male n/N (%) Unadjusted OR (†)
(95% CI)
p-value Adjusted OR (††)
(95% CI)
p-value
≥1 pathological imaging result 278/410 (68) 108/182 (59) 170/228 (75) 0.5 (0.33-0.76) 0.001* 0.43 (0.28-0.66) 0.0002*
Pathological WMH 154/410 (38) 74/182 (41) 80/228 (35) 1.3 (0.9-1.9) 0.25 1.13 (0.7- 1.7) 0.57
Old infarct 78/396 (20) 28/175 (16) 50/221 (23) 0.65 (0.4-1.1) 0.10 0.62 (0.4-1.0) 0.07
Lacunes 142/410 (35) 51/182 (28) 91/228 (40) 0.6 (0.4-0.9) 0.01* 0.53 (0.3-0.8) 0.003*
Microbleeds 76/410 (19) 33/182 (18) 43/228 (19) 0.95 (0.6-1.6) 0.85 0.93 (0.6-1.5) 0.78
Medial temporal lobe atrophy 125/410 (30) 34/182 (19) 91/228 (40) 0.35 (0.2-0.6) 0.001* 0.35 (0.2-0.6) 0.001*
Posterior atrophy 44/410 (11) 17/182 (9) 27/228 (12) 0.77 (0.4-1.5) 0.42 0.57 (0.3-1.1) 0.11
Evans index 17/410 (4) 6/182 (3) 11/228 (5) 0.67 (0.2-1.9) 0.44 0.7 (0.3-1.9) 0.49
The relationship between sex and pathological imaging findings was modelled using logistic regression with male sex as the reference group. Values are
displayed as frequencies (%) for all patients and grouped by sex
(*) indicates significant difference in pathological findings. WMH white matter hyperintensities, path pathology, Evans index measurement of ventricle size, OR
odds ratio. The analyses were adjusted for age to account for age as a potential confounding variable. (†)Unadjusted OR = OR for women compared to men.
(††)Adjusted OR = OR for women compared to men and adjusted for age. * indicating statistically significant odds ratio
Table 3 Distribution of imaging pathology and pre-stroke cognitive impairment
Pathological
Imaging group
N (%) GDS 1 N(%)
282 (69)







Normal 131 (32) 106 (81) 25 (19) 1 1
Cerebrovascular pathology 120 (29) 75 (62.5) 45 (37.5) 2.5 (1.4 to 4.5) 0.001* 2.0 (1.0 to3.7) 0.001*
Mixed pathology 99 (24) 55 (56) 44 (44) 3.4 (1.9 to 6.1) 0.001* 2.9 (1.5 to 5.7) 0.001*
Neurodegeneration 57 (14) 46 (81) 11 (19) 1.01 (0.5 to 2.2) 0.973 1.2 (0.6 to 2.7) 0.736
GDS Global Deterioration Scale, CI confidence interval. Values are displayed as absolute frequencies (%) for normal and pathological GDS grouped by dominating
imaging pattern (neurodegeneration, vascular pathology, mixed pathology or normal). Counts and frequencies are displayed for each sex separately. (†)
Unadjusted odds ratio (CI) for having a pathological GDS compared to the “normal” imaging group. (††) Odds ratio adjusted for age and education
* indicating statistically significant odds ratio. Baseline GDS scores were available for 407 patients out of 410 patients in this study
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all cases within 14 days to 6 months after stroke [2, 44].
We found MTA in 30% of participants.
Our findings of a 19% prevalence of microbleeds
amongst the participants is backed up by other findings
generally showing about twice as high a prevalence in
studies of cerebrovascular disease (22%) [43] compared
to a healthy ageing population (11%) [46].
In studies of patients aged 90 years and older, cerebro-
vascular disease is the most prevalent non-Alzheimer
age-associated pathology [47]. We found that 38% of the
study participants had pathological WMH levels. An-
other prospective stroke study found a comparable
prevalence of severe WMH in 30% of participants [36].
In the Rotterdam Scan Study, WMH were present in
95% of the subjects that were included from the general
population [48]. It seems there is an overlap between
normal aging and small vessel disease in the Rotterdam
study. Because of the omnipresence of WMH, we believe
that cut-offs should be used whenever possible for inter-
preting the visual rating scales [23] and they may serve
as practical tools in the follow-up of patients’ risk of
cognitive impairment [23].
The second aim of our study describe the association
between pre-stroke neuroimaging features and PCI. Pre-
vious studies have looked into the association of single
risk factors or single brain markers and post-stroke de-
mentia, even though it is known that mixed pathologies
of neurodegenerative and cerebrovascular changes are
common [49]. The highest numbers of patients with PCI
were found in the cerebrovascular- and the mixed group
that were significantly associated with PCI. Patients with
only markers of neurodegeneration were not associated
with PCI. This is in line with a study focusing on risk
factors for developing dementia that showed that iso-
lated pathologies improve the odds of being resilient
[11]. Further might the neurodegeneration be caused by
other mechanisms than AD like other neurodegenerative
diseases or systemic cardiovascular disease [50]. Robin-
son et al. also found that in the 90+ Study, resilient pa-
tients had less cerebrovascular disease [47]. However,
this is in conflict with the hypothesis that most of the
cognitive decline in a stroke population is only caused
by neurodegenerative changes [51]. The neurodegenera-
tive component in the mixed group has been linked to
small vessel disease and not to primary neurodegenera-
tive disease [51, 52], however, a recent study did not
confirm this link [53]. This highlights the importance of
considering mixed pathology in the etiology of PCI.
PCI was found in 19% of the patients with a normal-
appearing MRI and in almost double as many (36%) with
a pathological MRI.
There might be different explanations for why only
around one-third of the patients with imaging pathology
had PCI. First, it might be that the GDS scale has led to
a false-negative classification of some patients with PCI.
Secondly, this could be explained by differences in brain
resilience. Brain resilience relies both on factors affecting
cognitive reserve and brain reserve [11]. Previous studies
have shown that persons with high brain reserve can tol-
erate more brain pathology and be cognitively normal
for a longer time despite pathological imaging findings
on MR. [54]
In the same way, the 19% of the patients with a normal
appearing brain may have PCI due to reduced brain re-
silience. Based on our results, we cannot rule out re-
duced brain reserve as a consequence of a low total
brain volume or impaired structural connectivity [55].
More advanced imaging methods, like diffusion tensor
imaging (DTI), may be required to fully understand the
relation between brain changes and PCI. Psychological
stress has also been shown to impact cognitive outcome
after stroke, and to precede cardiovascular disease [56].
The third aim of our study was to investigate possible
sex differences in the risk of PCI. Comparing the risk
factors for stroke, the women in our study were signifi-
cantly older than the men, had higher pre-stroke disabil-
ity (measured by the mRS) and lower education, and
more often lived alone. Higher age is consistent with
previous stroke studies [16, 19]. However, the women
were equally likely as the men to have atrial fibrillation
and less likely to have hypertension even though previ-
ous studies have shown that women are more frequently
affected by both conditions [57]. In this study, more
men had hypertension and previous stroke, but not dia-
betes. This diverges from previous studies that have
shown more diabetes in men [57, 58]. The fact that the
observed sex-specific risk factor profile in our study dif-
fers from previous research might explain why we didn’t
observe a higher PCI risk for women. The risk of PCI
for women was not increased by the fact that more
women lived alone and had less education. These female
disadvantages may have been counterbalanced by their
lower burden of pathological imaging findings. In fact,
women had fewer lacunes and less medial temporal lobe
atrophy.
Both men and women in the cerebrovascular and
mixed groups had increased ORs for PCI. However, we
did not find a significant interaction between sex and
imaging pathology group. Our study therefore does not
confirm an increased risk of PCI in women as was
shown for pre-stroke dementia in the study by Pendle-
bury et al. [3].
A strength of this study is the large number of pro-
spectively included participants with good quality brain
MRIs. The application of cut-off values for visual ratings
is another strength that enabled us to categorize visual
scores as pathological and differentiate them from nor-
mal aging. A further strength of this study is the use of
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only visual rating scales. Visual rating scales have the ad-
vantage of robustness against reduced image quality,
they are fast and easy to perform and they do not re-
quire any specific software or hardware. This makes
them applicable in clinical practice.
A weakness is the lack of cognitive testing on all
participants who had MRI scans, which would have
given the study more statistical power. It was, however,
difficult to recruit some of the sickest patients, also po-
tentially leading to an underestimation of both chronic
pathology and PCI. Our patients suffered mainly mild
strokes. However, the patient population in the present
study has been found to be comparable to that of a gen-
eral stroke population [59]. This study raises awareness
of the high prevalence of brain imaging pathology even
in a stroke population suffering mainly minor strokes,
which is a strength. Future studies should investigate the
association of imaging markers and brain resilience more
closely.
Conclusions
Chronic brain pathology is common in stroke patients.
Vascular pathology and mixed pathology are more
important than neurodegeneration in the pathogenesis
of PCI. There is no significant sex difference for the risk
of PCI.
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